antitubercular antibiotics

Summary

Summary: Substances obtained from various species of microorganisms that are, alone or in combination with other agents, of use in treating various forms of tuberculosis; most of these agents are merely bacteriostatic, induce resistance in the organisms, and may be toxic.

Top Publications

  1. ncbi Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months
    C M Nolan
    Public Health, Seattle and King County, TB Control Program, Seattle, Washington, USA
    Int J Tuberc Lung Dis 6:952-8. 2002
  2. ncbi Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000
    Jiehui Li
    Bureau of Tuberculosis Control, New York City Department of Health and Mental Hygiene, New York, NY 10007, USA
    Clin Infect Dis 41:83-91. 2005
  3. ncbi Detection of rifampicin resistance in Mycobacterium tuberculosis isolates from diverse countries by a commercial line probe assay as an initial indicator of multidrug resistance
    H Traore
    Department of Microbiology, Institute of Tropical Medicine, Antwerp, Belgium
    Int J Tuberc Lung Dis 4:481-4. 2000
  4. pmc Evaluation of the INNO-LiPA Rif. TB assay, a reverse hybridization assay for the simultaneous detection of Mycobacterium tuberculosis complex and its resistance to rifampin
    R Rossau
    Innogenetics NV, Ghent, Belgium
    Antimicrob Agents Chemother 41:2093-8. 1997
  5. pmc Mycobacterium tuberculosis and rifampin resistance, United Kingdom
    I Ching Sam
    Health Protection Agency, National Mycobacterium Reference Unit, Institute of Cell and Molecular Science, Barts and the London School of Medicine, 2 Newark Street, London, United Kingdom
    Emerg Infect Dis 12:752-9. 2006
  6. ncbi Difficulties in anticoagulation management during coadministration of warfarin and rifampin
    C R Lee
    Division of Pharmacotherapy, School of Pharmacy, University of North Carolina at Chapel Hill, USA
    Pharmacotherapy 21:1240-6. 2001
  7. ncbi Evaluation of a colorimetric assay based on 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) for rapid detection of rifampicin resistance in Mycobacterium tuberculosis
    G Abate
    Department of Mycobacteriology, Statens Serum Institut, Copenhagen, Denmark
    Int J Tuberc Lung Dis 2:1011-6. 1998
  8. ncbi Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays
    J M Rae
    Department of Pharmacology, Georgetown University Medical Center, Washington, DC, USA
    J Pharmacol Exp Ther 299:849-57. 2001
  9. pmc Biological cost of rifampin resistance from the perspective of Staphylococcus aureus
    Thomas A Wichelhaus
    Institut fur Medizinische Mikrobiologie, Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt am Main, Germany
    Antimicrob Agents Chemother 46:3381-5. 2002
  10. pmc Use of genotype MTBDR assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis clinical strains isolated in Italy
    Paolo Miotto
    Emerging Bacterial Pathogens, San Raffaele Scientific Institute, Milan, Italy
    J Clin Microbiol 44:2485-91. 2006

Detail Information

Publications185 found, 100 shown here

  1. ncbi Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months
    C M Nolan
    Public Health, Seattle and King County, TB Control Program, Seattle, Washington, USA
    Int J Tuberc Lung Dis 6:952-8. 2002
    ..In 1992 the Seattle-King County Department of Public Health Tuberculosis Clinic began to treat patients with isoniazid-resistant tuberculosis with a regimen of isoniazid, rifampin, pyrazinamide, and ethambutol daily for 6 months...
  2. ncbi Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000
    Jiehui Li
    Bureau of Tuberculosis Control, New York City Department of Health and Mental Hygiene, New York, NY 10007, USA
    Clin Infect Dis 41:83-91. 2005
    ..The relationship between rifamycin use and either relapse or treatment failure with acquired rifampin resistance (ARR) among human immunodeficiency virus (HIV)-infected patients with tuberculosis (TB) is not well understood...
  3. ncbi Detection of rifampicin resistance in Mycobacterium tuberculosis isolates from diverse countries by a commercial line probe assay as an initial indicator of multidrug resistance
    H Traore
    Department of Microbiology, Institute of Tropical Medicine, Antwerp, Belgium
    Int J Tuberc Lung Dis 4:481-4. 2000
    ..This approach must therefore be validated in each local situation...
  4. pmc Evaluation of the INNO-LiPA Rif. TB assay, a reverse hybridization assay for the simultaneous detection of Mycobacterium tuberculosis complex and its resistance to rifampin
    R Rossau
    Innogenetics NV, Ghent, Belgium
    Antimicrob Agents Chemother 41:2093-8. 1997
    ..The INNO-LiPA Rif. TB is therefore a reliable and widely applicable assay and a valuable tool for routine diagnostic use, given its simplicity and rapid performance...
  5. pmc Mycobacterium tuberculosis and rifampin resistance, United Kingdom
    I Ching Sam
    Health Protection Agency, National Mycobacterium Reference Unit, Institute of Cell and Molecular Science, Barts and the London School of Medicine, 2 Newark Street, London, United Kingdom
    Emerg Infect Dis 12:752-9. 2006
    ..1%, 95.0%, 99.6%, 92.7%, and 99.7%, respectively. The assay enabled earlier diagnosis of MTBC and rifampin resistance (15.2 days) compared with culture-based techniques (30.7 days)...
  6. ncbi Difficulties in anticoagulation management during coadministration of warfarin and rifampin
    C R Lee
    Division of Pharmacotherapy, School of Pharmacy, University of North Carolina at Chapel Hill, USA
    Pharmacotherapy 21:1240-6. 2001
    ..Extensive changes in warfarin dosage are required to attain and maintain a therapeutic INR during the initiation, maintenance, and discontinuation of rifampin...
  7. ncbi Evaluation of a colorimetric assay based on 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) for rapid detection of rifampicin resistance in Mycobacterium tuberculosis
    G Abate
    Department of Mycobacteriology, Statens Serum Institut, Copenhagen, Denmark
    Int J Tuberc Lung Dis 2:1011-6. 1998
    ....
  8. ncbi Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays
    J M Rae
    Department of Pharmacology, Georgetown University Medical Center, Washington, DC, USA
    J Pharmacol Exp Ther 299:849-57. 2001
    ..Clinicians and researchers who use and study rifampin and other drugs that induce drug metabolism should be alert to the possibility of multiple effects...
  9. pmc Biological cost of rifampin resistance from the perspective of Staphylococcus aureus
    Thomas A Wichelhaus
    Institut fur Medizinische Mikrobiologie, Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt am Main, Germany
    Antimicrob Agents Chemother 46:3381-5. 2002
    ..The restriction to distinct mutations that confer rifampin resistance in vivo, as demonstrated here, appears to be determined by the Darwinian fitness of the organisms...
  10. pmc Use of genotype MTBDR assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis clinical strains isolated in Italy
    Paolo Miotto
    Emerging Bacterial Pathogens, San Raffaele Scientific Institute, Milan, Italy
    J Clin Microbiol 44:2485-91. 2006
    ..The MTBDR correctly identified the two cases of MDR-TB included in the panel. These results show that the MTBDR test is useful in the detection and management of tuberculosis when MDR disease is suspected...
  11. ncbi Rapid indication of multidrug-resistant tuberculosis from liquid cultures using FASTPlaqueTB-RIF, a manual phage-based test
    H Albert
    Biotec Laboratories Ltd, Johannesburg, South Africa
    Int J Tuberc Lung Dis 6:523-8. 2002
    ..A Mycobacteriology Reference Laboratory in Johannesburg, South Africa...
  12. ncbi Clinically significant interactions with drugs used in the treatment of tuberculosis
    W W Yew
    Tuberculosis and Chest Unit, Grantham Hospital, Aberdeen, Hong Kong, China
    Drug Saf 25:111-33. 2002
    ..With advancement of knowledge and expertise, it is hoped that therapeutic drug monitoring as a new paradigm of care can enable better management of these drug interactions...
  13. pmc A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis
    Maureen Morgan
    Division of Epidemiology, School of Public Health, University of California, Berkeley, USA
    BMC Infect Dis 5:62. 2005
    ..The INNO-LiPA Rif. TB (LiPA) is a commercial line probe assay designed to rapidly detect rifampicin resistance, a marker of MDR-TB. Although LiPA has shown promising results, its overall accuracy has not been systematically evaluated...
  14. ncbi Characterization of rpoB mutations in rifampin-resistant clinical Mycobacterium tuberculosis isolates from Kuwait and Dubai
    Suhail Ahmad
    Department of Microbiology, Faculty of Medicine, Kuwait University, P O Box 24923, 13110, Safat, Kuwait
    Diagn Microbiol Infect Dis 44:245-52. 2002
    ....
  15. pmc Characterization of rpoB mutations in rifampin-resistant clinical isolates of Mycobacterium tuberculosis from Turkey by DNA sequencing and line probe assay
    Cengiz Cavusoglu
    Department of Microbiology and Clinical Microbiology, School of Medicine, Ege University 35100, Izmir, Turkey
    J Clin Microbiol 40:4435-8. 2002
    ..6%). These results demonstrate that the line probe assay kit may be useful for the rapid diagnosis of rifampin-resistant tuberculosis...
  16. ncbi Mutations in rpoB gene and rifabutin susceptibility of multidrug-resistant Mycobacterium tuberculosis strains isolated in Australia
    V Sintchenko
    Centre for Infectious Diseases, Westmead Hospital, New South Wales, Australia
    Pathology 31:257-60. 1999
    ..tuberculosis predict rifabutin susceptibility for MDRTB. Use of the LiPA for RIF and rifabutin resistance may facilitate the rapid response required to limit the extent and severity of MDRTB transmission and infection...
  17. ncbi Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects
    Ann E Bolton
    Novartis Pharma AG, Basel, Switzerland
    Cancer Chemother Pharmacol 53:102-6. 2004
    ..This study was carried out to investigate the influence of CYP3A induction with rifampicin on imatinib (Gleevec) exposure...
  18. ncbi Rapid detection of resistance against rifampicin in isolates of Mycobacterium tuberculosis from Brazilian patients using a reverse-phase hybridization assay
    Martha M de Oliveira
    Laboratory of Molecular Biology and Diagnosis of Infectious Diseases, Department of Biochemistry and Molecular Biology, Oswaldo Cruz Institute, FIOCRUZ, Avenida Brasil 4365, Manguinhos 21045 900, Rio de Janeiro, Brazil
    J Microbiol Methods 53:335-42. 2003
    ....
  19. ncbi A newly identified 191A/C mutation in the Rv2629 gene that was significantly associated with rifampin resistance in Mycobacterium tuberculosis
    Qingzhong Wang
    State Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Sciences, Fudan University and Shanghai Pneumology Hospital, Shanghai, PRC
    J Proteome Res 6:4564-71. 2007
    ..tb Rv2629, while it was not restored by the wild type gene. These results indicate that the 191A/C mutation of the Rv2629 gene may be associated with RIF resistance...
  20. pmc Utility of an in-house mycobacteriophage-based assay for rapid detection of rifampin resistance in Mycobacterium tuberculosis clinical isolates
    N Gali
    Servei de Microbiologia, Hospital Universitari Germans Trias i Pujol, and Departament de Genètica i Microbiologia, Universitat Autonoma de Barcelona, Barcelona, Spain
    J Clin Microbiol 41:2647-9. 2003
    ..The sensitivity, specificity, and overall accuracy of the assay were 100%. This test is rapid to perform and suitable for widespread implementation...
  21. pmc Treatment outcomes of patients with HIV and tuberculosis
    Payam Nahid
    University of California, San Francisco, San Francisco General Hospital, 1001 Potrero Avenue, 5K1, San Francisco, CA 94110, USA
    Am J Respir Crit Care Med 175:1199-206. 2007
    ..The optimal length of tuberculosis treatment in patients coinfected with HIV is unknown...
  22. ncbi Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens
    Anton Mak
    Respiratory Epidemiology and Clinical Research Unit, Montreal Chest Institute, McGill University, Montreal, Canada
    Am J Respir Crit Care Med 178:306-12. 2008
    ..Multidrug-resistant tuberculosis (TB) poses a major challenge to global TB control. We analyzed the association between estimated prevalence of initial or acquired MDR-TB, and treatment outcomes reported nationally...
  23. pmc Low-cost rapid detection of rifampicin resistant tuberculosis using bacteriophage in Kampala, Uganda
    Hamidou Traore
    London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK
    Ann Clin Microbiol Antimicrob 6:1. 2007
    ..tuberculosis isolates for resistance to rifampicin. The purpose of this study was to investigate the performance of this technology in Kampala, Uganda...
  24. pmc Use of molecular methods to identify the Mycobacterium tuberculosis complex (MTBC) and other mycobacterial species and to detect rifampin resistance in MTBC isolates following growth detection with the BACTEC MGIT 960 system
    Akos Somoskovi
    Wadsworth Center, New York State Department of Health, Albany, New York, USA
    J Clin Microbiol 41:2822-6. 2003
    ..In conclusion, the biomass obtained in MGIT at the time of growth positivity in the 960 system is sufficient for use in all three molecular tests, and this approach can reduce the turnaround time for reporting results...
  25. ncbi Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial
    Debra Benator
    Lancet 360:528-34. 2002
    ..Rifapentine has a long half-life in serum, which suggests a possible treatment once a week for tuberculosis. We aimed to compare rifapentine and isoniazid once a week with rifampicin and isoniazid twice a week...
  26. ncbi Rifampin levels, interferon-gamma release and outcome in complicated pulmonary tuberculosis
    Helen McIlleron
    Department of Medicine, Division of Clinical Pharmacology, University of Cape Town, K 45 Old Main Buliding, Groote Schuur Hospital, Observatory, Cape Town, Western Cape 7925, South Africa
    Tuberculosis (Edinb) 87:557-64. 2007
    ..tuberculosis may influence treatment outcome. The data support the idea to identify persons at risk of a poor treatment outcome by monitoring of the in vitro response to tuberculosis antigens...
  27. ncbi Elevated gatifloxacin and reduced rifampicin concentrations in a single-dose interaction study amongst healthy volunteers
    Helen McIlleron
    Division of Clinical Pharmacology, Department of Medicine, Groote Schuur Hospital, University of Cape Town, South Africa
    J Antimicrob Chemother 60:1398-401. 2007
    ..Pharmacokinetic drug-drug interactions were investigated between the fluoroquinolone gatifloxacin and a fixed dose combination (FDC) of rifampicin, isoniazid and pyrazinamide...
  28. ncbi Simple, phage-based (FASTPplaque) technology to determine rifampicin resistance of Mycobacterium tuberculosis directly from sputum
    H Albert
    Biotec Laboratories Ltd, c o National Health Laboratory Service, Cape Town, Western Cape, South Africa
    Int J Tuberc Lung Dis 8:1114-9. 2004
    ..Cape Town, South Africa...
  29. ncbi The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis
    Frik A Sirgel
    Department of Cellular and Molecular Medicine, St George s Hospital Medical School, Cranmer Terrace, London SW17 0RE, United Kingdom
    Am J Respir Crit Care Med 172:128-35. 2005
    ..Comparison of the early bactericidal activity (EBA) of rifapentine and its pharmacokinetics with those of rifampin to determine the cause of poor clinical response and regrowth between doses, leading to rifamycin monoresistance at relapse...
  30. ncbi Evaluation of the line probe assay (LiPA) for rapid detection of rifampicin resistance in Mycobacterium tuberculosis
    Pontus Jureen
    Department of Bacteriology, Swedish Institute for Infectious Disease Control, Solna 17182, Sweden
    Tuberculosis (Edinb) 84:311-6. 2004
    ..The LiPA correctly identified the M. tuberculosis complex in all samples. The high accuracy and simplicity of LiPA makes it a very promising method for the early identification of rifampicin resistance in M. tuberculosis...
  31. ncbi Rifampin and rifabutin drug interactions: an update
    Christopher K Finch
    Department of Clinical Pharmacy, University of Tennessee, 26 S Dunlap, Suite 210, Memphis, TN 38163, USA
    Arch Intern Med 162:985-92. 2002
    ..New rifampin and rifabutin interactions will be discovered with further investigations...
  32. pmc Comparison of three molecular assays for rapid detection of rifampin resistance in Mycobacterium tuberculosis
    S A Watterson
    Public Health Laboratory Service Mycobacterium Reference Unit, Department of Microbiology, King s College School of Medicine and Dentistry, King s College Hospital Dulwich, London, United Kingdom
    J Clin Microbiol 36:1969-73. 1998
    ..7 and 100%), respectively. For the 21 isolates submitted by clinicians, both assays correlated 100% with routine testing...
  33. ncbi Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group
    W Zimmerli
    Department of Internal Medicine, University Hospitals, Basel, Switzerland
    JAMA 279:1537-41. 1998
    ..Rifampin-containing regimens are able to cure staphylococcal implant-related infections based on in vitro and in vivo observations. However, this evidence has not been proven by a controlled clinical trial...
  34. ncbi Description of new mutations in the rpoB gene in rifampicin-resistant Neisseria meningitidis selected in vitro in a stepwise manner
    Oliver Nolte
    Hygiene Institute, Dept of Hygiene and Medical Microbiology, University of Heidelberg, Im Neuenheimer Feld 324, D 69120 Heidelberg, Germany
    J Med Microbiol 52:1077-81. 2003
    ..Transformation of a PCR-amplified subgenic rpoB fragment harbouring the mutated site into a susceptible strain demonstrated the resistance-conferring mechanism...
  35. pmc Which contacts of patients with meningococcal disease carry the pathogenic strain of Neisseria meningitidis? A population based study
    B E Kristiansen
    Department of Medical Microbiology, University of Tromso, 9037 Tromso, Norway
    BMJ 317:621-5. 1998
    ..To determine the prevalence of the pathogenic strain of Neisseria meningitidis in contacts of patients with meningococcal disease, and to determine which contact groups are likely to be carriers and warrant chemoprophylaxis...
  36. pmc Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir
    Larissa A Wenning
    Merck and Co, Inc, Whitehouse Station, New Jersey, USA
    Antimicrob Agents Chemother 53:2852-6. 2009
    ..Coadministration of rifampin and raltegravir is not contraindicated; however, caution should be used, since raltegravir trough concentrations in the presence of rifampin are likely to be at the lower limit of clinical experience...
  37. ncbi Rapid screening of Mycobacterium tuberculosis for susceptibility to rifampicin and streptomycin
    R McNerney
    Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, UK
    Int J Tuberc Lung Dis 4:69-75. 2000
    ..To investigate rapid detection of drug-resistant tuberculosis using the genotypic Inno-LiPA Rif TB assay and a novel, low-cost, bacteriophage-based susceptibility assay...
  38. pmc In-house phage amplification assay is a sound alternative for detecting rifampin-resistant Mycobacterium tuberculosis in low-resource settings
    Norberto Simboli
    INEI ANLIS Carlos G Malbrán, Av Velez Sarsfield 563, 1281 Buenos Aires, Argentina
    Antimicrob Agents Chemother 49:425-7. 2005
    ..2% predictive value for resistance in a test of 129 isolates from a hot spot area of multidrug-resistant M. tuberculosis. The applicability of the test was demonstrated in the routine work flow of a low-resource reference laboratory...
  39. pmc Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease
    Prema Gurumurthy
    HIV AIDS Division, Tuberculosis Research Centre Indian Council of Medical Research, Mayor V R Ramanathan Rd, Chetput, Chennai 600 031, India
    Antimicrob Agents Chemother 48:4473-5. 2004
    ..HIV and HIV-tuberculosis patients who have diarrhea and cryptosporidial infection exhibit decreased bioavailability of antituberculosis drugs...
  40. pmc Testing of Mycobacterium tuberculosis susceptibility to ethambutol, isoniazid, rifampin, and streptomycin by using Etest
    A Wanger
    Department of Pathology, University of Texas Medical School, Houston 77030, USA
    J Clin Microbiol 34:1672-6. 1996
    ..The Etest method appears to be an alternative method for testing the susceptibility of M. tuberculosis isolates to the four most commonly used therapeutic agents...
  41. ncbi Treatment of multidrug-resistant tuberculosis: evidence and controversies
    J A Caminero
    Hospital de Gran Canaria Dr Negrin, Las Palmas de Gran Canaria, Spain
    Int J Tuberc Lung Dis 10:829-37. 2006
    ..individualised regimens. The evidence and controversies regarding each of the above questions are analysed with the aim of facilitating decision making in the treatment of these complex patients...
  42. ncbi Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy
    Marc Weiner
    Department of Medicine, South Texas Veterans Health Care System, San Antonio, Texas 78229, USA
    Am J Respir Crit Care Med 169:1191-7. 2004
    ..The present pharmacokinetic study supports further trials to determine the optimal rifapentine dose for treatment of tuberculosis...
  43. pmc Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis
    Ian M Rosenthal
    Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Am J Respir Crit Care Med 172:1457-62. 2005
    ..The substitution of moxifloxacin, a new 8-methoxyfluoroquinolone, for isoniazid and an increase in the dose of rifapentine could augment the activity of once-weekly regimens...
  44. ncbi Rifampicin resistance in Neisseria meningitidis: evidence from a study of sibling strains, description of new mutations and notes on population genetics
    O Nolte
    Hygiene Institute, Department of Hygiene and Medical Microbiology, University of Heidelberg, Germany
    J Antimicrob Chemother 39:747-55. 1997
    ..This finding is discussed with respect to recent studies that indicate a more panmictic population structure within particular serogroups of N. meningitidis...
  45. pmc Evaluation of phage assay for rapid phenotypic detection of rifampicin resistance in Mycobacterium tuberculosis
    Sergio Luis Yzquierdo
    Instituto de Medicina Tropical Pedro Kouri, La Habana, Cuba
    Ann Clin Microbiol Antimicrob 5:11. 2006
    ..Phage assay have been reported as a rapid useful tools for antimicrobial susceptibility testing. The aim of this study was to apply the Phage assay for rapid detection of resistance on Mycobacterium tuberculosis strains in Cuba...
  46. ncbi Emergence of rifampicin resistance in methicillin-resistant Staphylococcus aureus in tuberculosis wards
    Jun ichiro Sekiguchi
    International Medical Center of Japan, 1 21 1 Toyama, Shinjuku ku, Tokyo 162 8655, Japan
    J Infect Chemother 12:47-50. 2006
    ..An emergence of RFP-resistant MRSAs in tuberculosis wards in Japan was strongly suggested...
  47. ncbi Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia
    R van Crevel
    Department of Internal Medicine, University Medical Centre Nijmegen, The Netherlands
    Int J Tuberc Lung Dis 6:497-502. 2002
    ..High drug levels may lead to increased toxicity, while low drug levels may predispose to treatment failure and relapse...
  48. ncbi Rapid alternative methods for detection of rifampicin resistance in Mycobacterium tuberculosis
    Dihadenys Lemus
    Instituto de Medicina Tropical Pedro Kouri, La Habana, Cuba
    J Antimicrob Chemother 54:130-3. 2004
    ..To study the performance of three rapid low cost methods for the detection of rifampicin resistance...
  49. ncbi Cytochrome p450 3A4 messenger ribonucleic acid induction by rifampin in human peripheral blood mononuclear cells: correlation with alprazolam pharmacokinetics
    Isabella Gashaw
    Institute of Clinical Pharmacology, Charite University Medical Center, Humboldt University of Berlin, Berlin, Germany
    Clin Pharmacol Ther 74:448-57. 2003
    ..We also wanted to identify whether genetically determined high CYP3A5 expression is associated with increased alprazolam clearance...
  50. ncbi Intravenous cyclosporine-rifampin interaction in a pediatric bone marrow transplant recipient
    Elyse J Zelunka
    Division of Hematology Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada
    Pharmacotherapy 22:387-90. 2002
    ....
  51. ncbi Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone
    K Dilger
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Clin Pharmacol Ther 67:512-20. 2000
    ..Propafenone was chosen as a model drug because of its complex metabolism that permits the simultaneous in vivo assessment of induction of phase 1 and phase 2 pathways...
  52. ncbi Correlation of mutations detected by INNO-LiPA with levels of rifampicin resistance in Mycobacterium tuberculosis
    K Srivastava
    Department of Microbiology and Molecular Biology, Central JALMA Institute for Leprosy and Other Mycobacterial Diseases ICMR, Agra, India
    Indian J Med Res 120:100-5. 2004
    ..tuberculosis and correlate these mutations with levels of rifampicin resistance for assessing their clinical relevance...
  53. ncbi Another step on the path to better TB therapies
    Andrew Vernon
    Int J Tuberc Lung Dis 6:1-2. 2002
  54. pmc Rapid determination of rifampin resistance in clinical isolates of Mycobacterium tuberculosis by real-time PCR
    Tanil Kocagoz
    Department of Microbiology and Clinical Microbiology, Hacettepe University Faculty of Medicine, 06100 Sihhiye, Ankara, Turkey
    J Clin Microbiol 43:6015-9. 2005
    ..7% and a specificity of 100%. Real-time PCR is a very rapid method, and it can be especially helpful for the reporting of resistant clinical isolates in a very short period of time...
  55. ncbi Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis
    Y Bhusal
    Department of Laboratory Medicine, Graduate School and Faculty of Medicine, University of the Ryukyus, Nishihara Nakagami, Okinawa, Japan
    Int J Antimicrob Agents 26:292-7. 2005
    ..tuberculosis when combined with rifampicin and isoniazid...
  56. pmc Direct application of the INNO-LiPA Rif.TB line-probe assay for rapid identification of Mycobacterium tuberculosis complex strains and detection of rifampin resistance in 360 smear-positive respiratory specimens from an area of high incidence of multidrug
    Miguel Viveiros
    Unidade de Micobacterias do Instituto de Higiene e Medicina Tropical, Lisboa, Portugal
    J Clin Microbiol 43:4880-4. 2005
    ..7%; the sensitivity and specificity were 100.0% and 96.9%, respectively, for the detection of RIF resistance. This assay has the potential to provide rapid information that is essential for the effective management of MDR-TB...
  57. ncbi [Trends in tuberculosis treatment duration]
    Nicolas Veziris
    Service de Pneumologie, Assistance Publique Hopitaux de Paris, Centre National de Référence de la Résistance des Mycobactéries aux Antituberculeux, Faculte de Medecine Pierre et Marie Curie, Universite Paris 6
    Presse Med 35:1758-64. 2006
    ..New antituberculosis drugs under development allow us to envision further reduction in the duration of treatment of both drug-resistant and drug-sensitive tuberculosis...
  58. pmc Mycobacterium tuberculosis spoligotypes and drug susceptibility pattern of isolates from tuberculosis patients in peri-urban Kampala, Uganda
    Benon B Asiimwe
    Department of Medical Microbiology, Makerere University Medical School, Kampala, Republic of Uganda
    BMC Infect Dis 8:101. 2008
    ..This study determined the predominant strain lineages that cause TB in Rubaga division, Kampala, Uganda, and the prevalence of resistance to key anti-tuberculosis drugs in this community...
  59. ncbi [Considerations about the efficiency of treatment regimens with fixed Rifampicin-Isoniazid combinations in pulmonary tuberculosis]
    Ioana Munteanu
    Institutul de Pneumologie, Marius Nasta Bucureşti
    Pneumologia 53:23-5. 2004
    ....
  60. ncbi Bacteriophage-based assays for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a meta-analysis
    Madhukar Pai
    Division of Epidemiology, School of Public Health, University of California, 140, Warren Hall, Berkeley, CA 94720, USA
    J Infect 51:175-87. 2005
    ..To summarize, using meta-analysis, the accuracy of bacteriophage-based assays for the detection of rifampicin resistance in Mycobacterium tuberculosis...
  61. ncbi Factors associated with treatment success for tuberculosis patients: a single center's experience in Turkey
    Fahrettin Talay
    Department of Chest Diseases, Izzet Baysal Faculty of Medicine, Abant Izzet Baysal University, Bolu, Turkey
    Jpn J Infect Dis 61:25-30. 2008
    ..We conclude that application of Directly Observed Therapy may increase treatment success in all patients, especially patients who have risk factors for a low treatment success rate...
  62. ncbi Diffuse pachymeningitis due to Mycobacterium tuberculosis: a case report and review of the literature
    Thana Khawcharoenporn
    University of Hawaii John A Burns School of Medicine, Honolulu, HI 96813, USA
    Hawaii Med J 67:100-3. 2008
    ..Successful treatment with antituberculous drugs and corticosteroid was observed without complications. Literature review on characteristics, diagnoses and treatment of central nervous system tuberculosis was also performed...
  63. ncbi E-test: an alternative method for susceptibility testing of Mycobacterium tuberculosis
    Sinem Akcali
    Department of Microbiology and Clinical Microbiology, Celal Bayar University Medical Faculty, Manisa, Turkey
    Med Princ Pract 14:264-7. 2005
    ..The purpose of this study was to compare the agar proportion method with the E-test method for susceptibility testing of Mycobacterium tuberculosis...
  64. pmc Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model
    Ian M Rosenthal
    Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
    PLoS Med 4:e344. 2007
    ..Rifapentine is a long-lived rifamycin derivative currently recommended only in once-weekly continuation-phase regimens. Moxifloxacin is an 8-methoxyfluoroquinolone currently used in second-line regimens...
  65. ncbi Activity of ketoconazole against Mycobacterium tuberculosis in vitro and in the mouse model
    Sean T Byrne
    Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA
    J Med Microbiol 56:1047-51. 2007
    ..The lowest numbers of bacilli in lungs were found in mice treated with KTC, PZA and RIF. Further investigation is necessary to determine the role of KTC in the treatment of TB...
  66. pmc Comparison of two commercially available DNA line probe assays for detection of multidrug-resistant Mycobacterium tuberculosis
    Johanna Mäkinen
    Mycobacterial Reference Laboratory, National Public Health Institute, Kiinamyllynkatu 13, FI 20520 Turku, Finland
    J Clin Microbiol 44:350-2. 2006
    ..tuberculosis isolates obtained from patients suspected of having multidrug-resistant tuberculosis, but the GenoType MTBDR assay has the advantage of being able to detect resistance to both INH and RIF simultaneously...
  67. ncbi Impact of country of origin on drug-resistant tuberculosis among foreign-born persons in British Columbia
    A Moniruzzaman
    Department of Health Care and Epidemiology, University of British Columbia, Vancouver, British Columbia, Canada
    Int J Tuberc Lung Dis 10:844-50. 2006
    ..Provincial tuberculosis (TB) services, British Columbia, Canada...
  68. ncbi Comparison between molecular epidemiology, geographical regions and drug resistance in Mycobacterium tuberculosis strains isolated from Iranian and Afghan patients
    Rashid Ramazanzadeh
    National Research Institute of Tuberculosis and Lung Disease, Shaheed Beheshti University of Medical Sciences, Tehran, Iran
    Chemotherapy 52:316-20. 2006
    ..All M. tuberculosis isolates belonging to the Beijing family were associated with a resistance pattern. MDR was much higher in bacteria isolated from Afghan TB patients residing in Iran...
  69. pmc Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis
    Manzour Hernando Hazbón
    Division of Infectious Disease, Department of Medicine, University of Medicine and Dentistry of New Jersey, Newark, NJ 07103, USA
    Antimicrob Agents Chemother 50:2640-9. 2006
    ..Our results suggest that isoniazid resistance and the evolution of multidrug-resistant strains are complex dynamic processes that may be influenced by interactions between genes and drug-resistant phenotypes...
  70. pmc Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis
    Eric Nuermberger
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Antimicrob Agents Chemother 50:2621-5. 2006
    ....
  71. ncbi [Mechanisms of action of and resistance to rifampicin and isoniazid in Mycobacterium tuberculosis: new information on old friends]
    A I De La Iglesia
    Catedra de Microbiologia, Virologia y Parasitologia, Facultad de Ciencias Medicas, Universidad Nacional de Rosario, Santa Fe 3100 2000 Rosario, Argentina
    Rev Argent Microbiol 38:97-109. 2006
    ..Other mutations causing resistance to isoniazid have been mapped to ndh, a gene encoding the NADH dehydrogenase...
  72. ncbi Evaluation of the rpoB macroarray assay to detect rifampin resistance in Mycobacterium tuberculosis in Beijing, China
    I Mokrousov
    Laboratory of Molecular Microbiology, St Petersburg Pasteur Institute, 14 Mira Street, 197101, St Petersburg, Russia
    Eur J Clin Microbiol Infect Dis 25:703-10. 2006
    ..The RIFO method is relatively simple to perform and allows straightforward interpretation of results; consequently, it can be used in clinical diagnostic laboratories as a fast complement to phenotypic methods...
  73. ncbi Validation of a rapid method for detection of M. tuberculosis resistance to INH and RMP in Lima, Peru
    Isabel N de Kantor
    Int J Tuberc Lung Dis 10:707; author reply 707-8. 2006
  74. ncbi [Modern diagnosis of tuberculosis]
    Chantal Truffot-Pernot
    Laboratoire de Bacteriologie Hygiene, Centre National de Référence Mycobactéries et Résistance des Mycobactéries aux Antituberculeux, Groupe Hospitalier Pitie Salpetriere, Paris
    Presse Med 35:1739-46. 2006
    ..Immunologic tests that measure the interferon gamma produced by sensitized lymphocytes are promising tools for the diagnosis of latent tuberculosis...
  75. ncbi Absence of an association between Mycobacterium tuberculosis genotype and clinical features in children with tuberculous meningitis
    Freda Maree
    Desmond Tutu TB Centre, Department of Pediatrics and Child Health, Stellenbosch University, Stellenbosch, South Africa
    Pediatr Infect Dis J 26:13-8. 2007
    ..We investigated mycobacterial genotypic diversity in children with TBM and analyzed the relationship among genotype, clinical presentation and outcome...
  76. ncbi [Centrofacial granulomatous inflammation]
    J Maetzke
    Klinik für Dermatologie und Allergologie, Universitatsklinikum Ulm, Maienweg 12, 89081 Ulm
    Hautarzt 58:976-8. 2007
  77. pmc Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910
    Anne J Lenaerts
    Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523, USA
    Antimicrob Agents Chemother 51:3338-45. 2007
    ..These results show that this acellular rim may, therefore, be a primary location of persisting bacilli withstanding drug treatment...
  78. ncbi Drug resistance in tuberculosis
    G J Ebrahim
    J Trop Pediatr 53:147-9. 2007
  79. pmc Comparison of a conventional antimicrobial susceptibility assay to an oligonucleotide chip system for detection of drug resistance in Mycobacterium tuberculosis isolates
    Heekyung Park
    Institute for Genomic Medicine, GENEIN Co, Ltd, Busan, Korea
    J Clin Microbiol 44:1619-24. 2006
    ..The diagnostic oligonucleotide chip with mutation-specific probes is a reliable and useful tool for the rapid and accurate diagnosis of resistance against rifampin and isoniazid in M. tuberculosis isolates...
  80. ncbi The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis
    Roly D Gosling
    Department of Medical Microbiology, Royal Free and University London College Medical Schools, Royal Free Campus, London, UK
    Am J Respir Crit Care Med 168:1342-5. 2003
    ..Moxifloxacin has an activity similar to rifampin in human subjects with pulmonary tuberculosis, suggesting that it should undergo further assessment as part of a short course regimen for the treatment of drug-susceptible tuberculosis...
  81. ncbi In vitro activity of C-8-methoxy fluoroquinolones against mycobacteria when combined with anti-tuberculosis agents
    Tao Lu
    Public Health Research Institute, 225 Warren Street, Newark, NJ 07103, USA
    J Antimicrob Chemother 52:1025-8. 2003
    ..To examine the effect of first-line and second-line anti-tuberculosis agents on the ability of fluoroquinolones to kill mycobacteria...
  82. ncbi Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis
    Rajesh Pandey
    Department of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh 160 012, India
    J Antimicrob Chemother 52:981-6. 2003
    ..e. rifampicin, isoniazid and pyrazinamide encapsulated in poly (DL-lactide-co-glycolide) nanoparticles suitable for nebulization...
  83. ncbi Relative versus absolute noncontagiousness of respiratory tuberculosis on treatment
    Richard Long
    Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
    Infect Control Hosp Epidemiol 24:831-8. 2003
    ..To assess the validity of current estimates of the noncontagiousness of sputum smear-positive respiratory tuberculosis (TB) on treatment...
  84. ncbi Typing of Mycobacterium tuberculosis strains resistant to rifampicin and isoniazid by molecular biological methods
    O I Skotnikova
    Moscow Tuberculosis Control Center, Moscow Public Health Committee
    Bull Exp Biol Med 136:273-5. 2003
    ..Twenty-five combinations of mutations were detected. Some differences in the type distribution of detected mutations were found. The use of biochips is the most perspective method for determining the type of mutation...
  85. ncbi Effect of drug resistance on the generation of secondary cases of tuberculosis
    Marcos Burgos
    Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University Medical Center, Stanford, California, USA
    J Infect Dis 188:1878-84. 2003
    ..Here, we assess the relative pathogenicity of drug-resistant and drug-susceptible strains, in a human population...
  86. ncbi [Septic loosening of a Wagner revision stem provoked by Mycobacterium tuberculosis]
    A Schuh
    Orthopädische Klinik Rummelsberg, Schwarzenbruck
    Orthopade 32:1151-4. 2003
    ..Until today the patient exhibits no signs of recurrence of the tuberculous infection...
  87. ncbi [Clinical forms of new cases of tuberculosis at Kaunas Romainiai Tuberculosis Hospital in 1998-2001]
    Albinas Naudziunas
    Clinic of Internal Medicine, Kaunas University of Medicine, A Mickeviciaus 9, 44307 Kaunas, Lithuania
    Medicina (Kaunas) 40:42-5. 2004
    ..Multi-drug resistant tuberculosis did not exceed 1%. We suggest that so few cases of multi-drug resistant tuberculosis are due to implementation of WHO treatment standards...
  88. ncbi [Tuberculous pneumonia in children]
    Dalia Steponaviciene
    Department of Children Pulmonology, Kaunas IInd Clinical Hospital, Lithuania
    Medicina (Kaunas) 39:225-31. 2003
    ..Two clinical cases of children ill with TB pneumonia are discussed as well. We hope that this article and two clinical cases would remind pediatricians and family doctors to be aware of still possible TB in childhood...
  89. ncbi Treatment outcome of tuberculosis among Saudi nationals: role of drug resistance and compliance
    Y Samman
    Department of Respirology, King Khalid National Guard Hospital, Jeddah, Saudi Arabia
    Clin Microbiol Infect 9:289-94. 2003
    ..In this study, we assessed the impact of this and other factors on the treatment outcome of tuberculosis among Saudi nationals...
  90. ncbi Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days
    Amina Jindani
    Clinical Trials Program, International Union Against Tuberculosis and Lung Disease, Paris, France
    Am J Respir Crit Care Med 167:1348-54. 2003
    ..In analyses of combined drug regimens only, ethambutol had an effect (p = 0.01) in reverse direction to that of rifampin, suggesting it antagonized the sterilizing activity of other drugs...
  91. ncbi Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes
    Sumeet Labana
    Department of Biochemistry, Postgraduate Institute of Medical Education and Research, 160 012, Chandigarh, India
    Int J Antimicrob Agents 20:301-4. 2002
    ..392) and RIF (-0.243). Chemotherapeutic efficacy of once weekly-administered liposomal drugs for 6 weeks reduced the mycobacterial load significantly in lungs, liver and spleen of infected mice compared with untreated animals...
  92. pmc Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase
    A Lissa B Gerum
    Department of Genome Sciences, University of Washington, Seattle, Washington 98195 7730, USA
    Antimicrob Agents Chemother 46:3362-9. 2002
    ..tuberculosis DHFR. These studies suggest that compounds of this class are excellent potential leads for further development of drugs effective against M. tuberculosis...
  93. ncbi Results of a 12-month regimen for drug-resistant pulmonary tuberculosis
    C Perez-Guzman
    Instituto Nacional de Enfermedades Respiratorias, Mexico DF, Mexico
    Int J Tuberc Lung Dis 6:1102-9. 2002
    ..Several therapeutic regimens for drug-resistant tuberculosis have been suggested, most of them with a total duration of 18-24 months...
  94. ncbi Influence of anti-tuberculosis drug resistance on the treatment outcome of pulmonary tuberculosis patients receiving DOTS in Riyadh, Saudi Arabia
    R Singla
    Department of Tuberculosis and Chest Diseases, Sahary Hospital, Riyadh, Kingdom of Saudi Arabia
    Int J Tuberc Lung Dis 6:585-91. 2002
    ....
  95. ncbi Use of receiver operating characteristic curves to assess the performance of a microdilution assay for determination of drug susceptibility of clinical isolates of Mycobacterium tuberculosis
    J Luna-Herrera
    Departamento de Inmunologia, Instituto Politecnico Nacional, Escuela Nacional de Ciencias Biologicas, Carpio y Plan de Ayala, Colonia Santo Tomás 11340, Mexico City, Mexico
    Eur J Clin Microbiol Infect Dis 22:21-7. 2003
    ..The ROC curve analysis is a robust statistical approach for evaluating the performance of new quantitative methods for determination of drug sensitivity of Mycobacterium tuberculosis isolates...
  96. ncbi Use of molecular techniques to distinguish between treatment failure and exogenous reinfection with Mycobacterium tuberculosis
    Annika Kruuner
    Institute of Microbiology, Tartu University, Estonia
    Clin Infect Dis 35:146-55. 2002
    ..Exogenous reinfection with drug-resistant M. tuberculosis may be misinterpreted as the emergence of drug resistance if molecular testing techniques are not used...
  97. ncbi [Mycobacterium tuberculosis resistance to antitubercular agents in Antananarivo in 2000]
    O Ratsirahonana
    Laboratoire des Mycobactéries, Institut Pasteur de Madagascar, BP 1274 101 Antananarivo Madagascar
    Arch Inst Pasteur Madagascar 68:44-7. 2002
    ..1% for primary MDR and 4% for acquired MDR. These results show that ten years after the new NTP implementation, only a few MDR strains are circulating in Antananarivo, which suggests that NTP has been effective...
  98. ncbi Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model
    Rajesh Pandey
    Department of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh 160 012, India
    J Antimicrob Chemother 54:266-8. 2004
    ..Hence, injectable PLG nanoparticles hold promise for increasing drug bioavailability and reducing dosing frequency for better management of tuberculosis...
  99. ncbi Tuberculosis in Thai prisons: magnitude, transmission and drug susceptibility
    S Sretrirutchai
    Department of Pathology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Thailand
    Int J Tuberc Lung Dis 6:208-14. 2002
    ..Prison inmates are at high risk for developing tuberculosis because of the high prevalence of HIV infection...
  100. ncbi Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in Poly (DL-lactide-co-glycolide) microparticles
    M Dutt
    Department of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh 160 012, India
    J Antimicrob Chemother 47:829-35. 2001
    ..These results suggest that PLG microparticles offer an improvement for tuberculosis chemotherapy over the conventional treatment...
  101. pmc Rapid direct detection of multiple rifampin and isoniazid resistance mutations in Mycobacterium tuberculosis in respiratory samples by real-time PCR
    Mercedes Marin
    Servicio de Microbiologia Clinica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Maranon, C Dr Esquerdo 46, 28007 Madrid, Spain
    Antimicrob Agents Chemother 48:4293-300. 2004
    ..tuberculosis bacteria. This real-time PCR design is an adequate method for the specific and rapid detection of RIF and INH resistance in smear-positive clinical respiratory samples...

Research Grants26

  1. Defining Moxifloxacin as a First-line TB Drug
    Eric Nuermberger; Fiscal Year: 2008
    ..Relevance: Results of these studies will help to define optimal treatment regimens for TB that can be used to design new clinical trials or, in some cases, directly applied to clinical practice. ..
  2. DENVER COMMUNITY PROGRAM FOR CLINICAL RESEARCH ON AIDS (
    David Cohn; Fiscal Year: 2007
    ..abstract_text> ..
  3. NEW ENGLAND PROGRAM FOR AIDS CLINICAL TRIALS-PROACT (CPC
    Gerald Friedland; Fiscal Year: 2006
    ..Among the three ProACT sites we will enroll and follow 200 patients on study protocols at any given time over the course of this grant. ..
  4. Role of non-tuberculous mycobacteria in lung disease
    Jason Stout; Fiscal Year: 2006
    ..Our findings will also assist clinicians in predicting which patients with NTM isolated from the respiratory tract will have NTM pulmonary disease. ..
  5. Attachment of Oral Actinobacillus to Epithelium
    Daniel Fine; Fiscal Year: 2008
    ..The longterm goal of this application is to use this information to identify targets for therapeutic agents that can interfere with attachment of Aa to oral tissues and thus prevent colonization leading to LAP. [unreadable] [unreadable]..
  6. Safety Pharmacokinetics & Efficacy of Artemether & Lumefantrine in Pregnant Women
    Mark Mirochnick; Fiscal Year: 2008
    ..The data from this planned study will provide the information needed to ensure that pregnant women receive the appropriate doses of these anti-malaria drugs. [unreadable] [unreadable] [unreadable]..
  7. Antiretroviral Pharmacology/Lactating Mother/Infants
    Mark Mirochnick; Fiscal Year: 2006
    ..This information is needed for the safe and effective use of antiretrovirals in nursing women, and will pioneer a novel approach to the study of breast milk drug transfer. ..
  8. Maternal and Infant Health and HAART Outcomes in the Mashi PMTCT Study, Botswana
    Shahin Lockman; Fiscal Year: 2010
    ..placebo exposure;and pediatric neurodevelopmental and growth outcomes, by infant feeding modality and antiretroviral exposure history. ..
  9. Oral Immunology/Microbiology Research Group Annual Mtg
    Daniel Fine; Fiscal Year: 2003
    ..Perpetuation of the OIMRG and its annual meetings greatly enhances the spirit of collegial interaction/collaboration among investigators with expertise in immunology and microbial pathogenesis as related to oral health and disease. ..
  10. Discovering New Anti-Tuberculosis Drugs
    MICHAEL GEORGE THOMAS; Fiscal Year: 2010
    ..This will be accomplished by combining genetic and molecular engineering of the tuberactinomycin biosynthetic pathways, along with semi-synthetic chemistry. ..
  11. Effectiveness of Alcohol Interventions Among TB Patients in Tomsk, Russia
    Sonya Shin; Fiscal Year: 2008
    ..Finally, we have a diverse interdisciplinary team that has been able to formulate an integrated biosocial and culturally-appropriate approach to treating AUDs in this population. [unreadable] [unreadable] [unreadable]..
  12. Oral Immunology/Microbiology Annual Meeting
    Daniel Fine; Fiscal Year: 2003
    ..Perpetuation of the OIMRG and its annual meetings greatly enhances the spirit of collegial interaction/collaboration among investigators with expertise in immunology and microbial pathogenesis as related to oral health and disease. ..
  13. Training in Translational Lung Research
    Neil Schluger; Fiscal Year: 2008
    ..abstract_text> ..
  14. TB Clinical Research: Training the Next Generation
    Carol Hamilton; Fiscal Year: 2008
    ..Her work with the Duke Center for Human Genetics is an example of translational research she hopes to foster within her mycobacteria research program. ..
  15. RESPIRATORY DISEASES/BSI STUDY
    Shahin Lockman; Fiscal Year: 2004
    ....
  16. Combination Antibotics as a Treatment for Chlamydia-Induced Reactive Arthritis
    John Carter; Fiscal Year: 2007
    ..Chronic Chlamydia infections have also been linked to trachoma, tubal infertility, coronary artery disease, asthma, certain types of cervical cancer, and possibly other diseases. [unreadable] [unreadable] [unreadable]..
  17. IVIVC MODEL FOR RENAL DRUG CLEARANCE
    Thomas Dowling; Fiscal Year: 2005
    ..abstract_text> ..
  18. Psychosocial Intervention in HIV-Affected Children in Haiti
    Joia Mukherjee; Fiscal Year: 2006
    ..Lastly, a group intervention for HIV affected children will be piloted to generate preliminary data for a larger, R01 study designed to prevent poor outcomes in HlV-affected children. ..
  19. Novel Single Cell Reporter Gene Assay
    Yevgenya Akselband; Fiscal Year: 2005
    ..This assay will facilitate drug discovery by permitting rapid screening of combinatorial chemistry or natural product libraries. ..
  20. Functional Genomics Study and Database for Tuberculosis
    Li Fu; Fiscal Year: 2006
    ..Research results will advance molecular biological knowledge and benefit public health management in tuberculosis. ..
  21. Evaluation of MDR-TB Treatment Strategies in Lima, Peru
    Sonya Shin; Fiscal Year: 2006
    ..abstract_text> ..
  22. Re-Engineering the Clinical Research Enterprise
    Carol Hamilton; Fiscal Year: 2004
    ..Create an interoperable, secure web-based electronic data capture system for the TBTC, that will interface with public health surveillance systems...
  23. Human Metabolism of Anti-Abuse Medications
    David Moody; Fiscal Year: 2005
    ..We anticipate these studies will provide the evidence to support clinical studies to more thoroughly test our hypothesis. ..
  24. Microbial Markers for Periodontal Disease in Children
    Daniel Fine; Fiscal Year: 2005
    ....
  25. Nanoparticle delivery system for antiturberculosis drug
    Leonid Heifets; Fiscal Year: 2004
    ..abstract_text> ..